Immunovant Inc
IMVT
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.84B
Close$
$4.94
84.1% downside
Current Fair Value
84.1% downsideOvervalued by 84.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $6.84 Billion |
|---|---|
| Enterprise Value | $5.93 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.77 |
| Beta | 0.7 |
| Outstanding Shares | 203,709,320 |
Return
| Return on Equity | -59.30% |
|---|---|
| Return on Assets | -52.83% |
| Return on Invested Capital | -48.21% |
Valuation & Multiples
| P/E Ratio | -13.42 |
|---|---|
| PEG | -34.49 |
| Price to Sales | - |
| Price to Book Ratio | 7.79 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -14.44 |
| Enterprise Value to Net Income | -12 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 28, 2026
EPS Estimate
$-0.61
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
June 4, 2026
EPS Estimate
$-0.60
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1046▼ 8.97% |
|---|---|
| Total Calls | 2,511,900▲ 106.74% |
| Total Puts | 262,800▲ 11.31% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 60.93%▼ 1.62% |
|---|---|
| Total Invested | $2.75B▼ 0.52% |
| Investors Holding | 226▲ 18.00% |
ESG Score
No data